1 published article · Updated continuously
14 trials tracked for Rheumatic Diseases: 2 in phase 3 or 4 and 1 with published results. The most-cited published study has 63 citations.
Showing the 14 most-cited and recently-updated of 14 trials. Browse the full registry →
Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.
In a large-scale study, Rivaroxaban (10 mg) was evaluated for safety and efficacy in patients with rheumatic conditions. The time to the first occurrence of a composite of all symptomatic venous thromboembolism (VTE) and VTE-related death was 0.84 vs. 1.11 (p=0.136), while major bleeding rates were 0.28 vs. 0.15 (p=0.124). The rate of VTE-related death was 0.72 vs. 0.77 (p=0.751) 1.
Treatment with TNX-102 SL Tablet (2.8mg) resulted in significant improvements in fibromyalgia symptoms and function at week 12. Specifically, the Fibromyalgia Impact Questionnaire - Revised (FIQR) Symptoms Domain Score changed from baseline by -8.2 vs. -14.1 2, and the FIQR Function Domain Score changed by -4.4 vs. -10.3 2.
AI synthesis of 3 cited trials, updated Jul 16, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.
